Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Life Science Investing
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity Life Science Investing
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer Life Science Investing
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights Biotech Investing
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates Life Science Investing
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Biotech Investing
PharmaTher Establishes PERSONALIZ3D to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing Life Science Investing
Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders Life Science Investing
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Biotech Investing
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Life Science Investing
